A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell non-Hodgkin Lymphoma (Glo-BNHL)

The Glo-BNHL trial is the largest platform trial in paediatric and adolescent relapsed and refractory B-cell malignancies globally. 

It has been developed in collaboration with a number of international partners, including Innovative Therapies for Children with Cancer (ITCC) and European Intergroup for Childhood NHL (EICNHL) in Europe; Children's Oncology Group (COG) and C¹⁷  in North America; and the Australia and New Zealand Children’s Haematology and Oncology Group (ANZCHOG).

The platform is aiming to test a wide range of therapies over the lifetime of the trial with the aim of finding better treatments and, ultimately, a cure for this rare paediatric cancer.

For patients and public

Find out more about the trial and how to get involved

For professionals

Find out more about the trial design and access our publications

For participating sites

Access information for hospitals and download current trial documentation

For industry partners

Find out further information on current industry partners, trial design and contractual arrangements

Also in 'Glo-BNHL'

• For patients and public
• For professionals
• Participating sites
• For industry partners
• Meet the Team
• Our funders and collaborators
• Contact us